Release Date: August 08, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you provide more color on how the new services agreement with Roche has enhanced the partnership, particularly regarding manufacturing scale? A: Brian Culley, CEO: The services agreement, entered after Genentech had time to form an opinion on the OpRegen program, includes a five-year follow-up for Phase 1/2a patients, indicating enthusiasm for the program. Lineage continues to manufacture clinical material for OpRegen, with plans for Roche/Genentech to eventually take over commercial manufacturing. The tech transfer process is lengthy, requiring personal training to ensure quality.
Q: Does your current cash guidance include future milestone payments from Roche? A: Jill Howe, CFO: No, the current cash runway does not include potential milestone payments. We are being thoughtful and conservative with our cash management to navigate the tough environment.
Q: What activities are planned for the OPC1 study, particularly around patient identification and screening? A: Brian Culley, CEO: We can prepare sites with training and protocol discussions but cannot involve patients until the IND is open. We hypothesize that identifying chronic injury patients will be easier than subacute ones, and we plan to use social media and community relationships to support patient outreach once permitted.
Q: How quickly could you access CIRM capital to run the DOSED study once the IND is cleared? A: Jill Howe, CFO: There will be a delay due to CIRM's influx of applications, but we maintain good communication with them. The funding will be gradual over time as we progress through the trial.
Q: Are there plans to move preclinical programs like ANP1 into functional models or IND-enabling studies soon? A: Brian Culley, CEO: We are making modest, impactful investments in early-stage programs while waiting for OpRegen data. Our strategy is to use OpRegen's success to advance these programs affordably in the future.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.